Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDUCE trial: paclitaxel + bevacizumab induction followed by atezolizumab + nab-paclitaxel vs standard atezolizumab + nab-paclitaxel in PD-L1-positive metastatic TNBC
jRCTs041240039Phase 2Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of paclitaxel, bevacizumab and atezolizumab in breast cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Jun 2024; status: recruiting.
02
Drugs
paclitaxelbevacizumabatezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs041240039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240039.